GeneticTesting.com
← All newsIndustry

Illumina and Lucence Selected to Power Singapore's National Genome Sequencing Project

Illumina and Lucence Selected to Power Singapore's National Genome Sequencing Project

2026-11-19

Singapore has named Illumina and Lucence as chosen partners for its national genome sequencing project, marking a significant operational milestone for one of the most ambitious precision medicine programmes in the Asia-Pacific region. The selection cements the country's commitment to building a robust genomic data infrastructure that can support both clinical care and translational research at a population level.

The Technology

The pairing of Illumina and Lucence represents a deliberate layering of sequencing capability. Illumina brings its established short-read sequencing platforms, which remain the workhorse technology for large-scale population genomics due to their throughput, accuracy, and relatively mature bioinformatics ecosystem. Lucence, a Singapore-founded liquid biopsy and genomics company, adds a complementary dimension with its expertise in cell-free DNA analysis and oncology-focused sequencing applications. Together, the two organisations are positioned to serve both the germline population sequencing goals of the broader National Precision Medicine strategy and the somatic or clinical oncology testing demands that health systems increasingly require. The dual-vendor structure also suggests Singapore's planners are building in resilience and functional specialisation rather than relying on a single sequencing pathway.

Clinical Context

Singapore's National Precision Medicine programme has been building toward this point for several years. A July 2026 paper in Nature detailed how the programme is working to translate genomic data directly into healthcare practice, underscoring that the ambition extends well beyond data collection into active clinical utility. The selection of sequencing partners is therefore not merely a procurement decision but a foundational step in embedding genomics into standard care pathways across the country's public health system. Singapore's multi-ethnic population, encompassing Chinese, Malay, Indian, and other ancestral groups, also makes it a scientifically valuable cohort for understanding how genetic variants manifest across diverse Asian ancestries, an area where global genomic databases have historically been underrepresented. Generating high-quality, population-representative sequencing data at scale addresses a gap that has real consequences for the accuracy of polygenic risk scores and pharmacogenomic recommendations across Southeast Asian patients.

What's Next

With sequencing partners now in place, attention will turn to the data governance frameworks, clinical reporting pipelines, and healthcare workforce capabilities needed to convert raw genomic output into actionable clinical decisions. Integrating findings into electronic health records, training clinicians to interpret genomic reports, and establishing consent and data-sharing protocols will define whether the programme delivers on its precision medicine promise. For the broader genetic testing industry, Singapore's model of structured national investment combined with carefully selected commercial sequencing partners offers a replicable blueprint that other health systems across Asia and beyond are likely to study closely as they chart their own genomic medicine strategies.

Stay ahead in genomics

Funding rounds, FDA clearances, and precision-medicine moves — weekly, free.